海利生物(603718.SH):瑞盛生物的GORORISE可吸收胶原膜产品获得MOH批准

智通财经网
Apr 07

智通财经APP讯,海利生物(603718.SH)发布公告,公司控股子公司陕西瑞盛生物科技有限公司(以下简称“瑞盛生物”)于2025年12月向印度尼西亚卫生部(以下简称“MOH”)递交了瑞盛生物GORORISE Resorbable Collagen Membrane (GORORISE 可吸收胶原膜)产品的注册申报资料。瑞盛生物于近日收到MOH通知,瑞盛生物的GORORISE可吸收胶原膜产品获得MOH的批准。

本次获得印度尼西亚注册证的GORORISE可吸收胶原膜是瑞盛生物研发和生产的一种脱细胞基质材料(Decellularized extracellular matrix,dECM)。临床患者牙缺失后,缺牙部位的牙槽骨常因缺乏功能性刺激而发生进行性吸收,进而导致种植牙时面临骨量不足的问题。针对此问题,可吸收胶原膜与口腔用骨填充材料联合使用,在口腔种植手术中用于重建缺失牙患者口内种植区的牙槽骨骨组织,解决缺失牙患者口内种植区水平或垂直骨量不足时阻止软组织中成纤维细胞及上皮细胞长入,为增殖速度较慢的成骨细胞优先进入骨缺损区提供时间与空间,引导骨组织/牙周组织再生。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10